Mizuho Securities analyst Vamil Divan maintained a Buy rating on AbbVie (NYSE:ABBV) on Wednesday, setting a price target of $126, which is approximately 16.76% above the present share price of $107.91.
Divan expects AbbVie to post earnings per share (EPS) of $0.02 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in AbbVie, with an average price target of $127.
The analysts price targets range from a high of $144 to a low of $115.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $13.86 billion and a net profit of $4.05 billion. The company's market cap is $190.44 billion.
According to TipRanks.com, Mizuho Securities analyst Vamil Divan is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -1.9% and a 48.28% success rate.
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.